{
  "docId": "019de072-4935-7342-8528-4e6eca3fe5c7",
  "docSlug": "31ea92baba83669e6443d115d329d67b",
  "documentTitle": "AstraZeneca | Investor Presentation Deck | 53 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 53,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses a three-column layout to present product-specific updates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4935-7342-8528-4e6eca3fe5c7/26",
  "deckHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7",
  "deckJsonHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7.json",
  "deckAnchorHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.12,
        "x": 0.51,
        "y": 0.74
      },
      "kind": "image",
      "text": "Vaxzevria product packaging",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e096298-d85b-47fb-b9a9-3d211b550083",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.12,
        "x": 0.21,
        "y": 0.73
      },
      "kind": "image",
      "text": "Evusheld product packaging",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b07284b9-77a1-4ddf-be28-be11bef9687a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "list",
      "text": "Vaxzevria: Clinical and real-world evidence supports use as booster. 2.5bn doses supplied in 2021. Boosts immune response against Omicron. Retains neutralising activity after two-doses. Vaxzevria and AZD2816 - generated similar immune response to variants of concern.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "181d0036-13df-4071-8ae4-f60151fc6c9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.67,
        "y": 0.25
      },
      "kind": "list",
      "text": "eplontersen: ATTR. Collaboration with Ionis Pharmaceuticals. ATTR: misfolded protein and accumulation as amyloid fibrils. Phase III trials: CARDIO-TTRansform (data 2023+) NEURO-TTRansform (data H2 2022)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37ffe52f-43da-4af7-a960-6538f509c052",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": "Evusheld: Only long-acting antibody combination shown to prevent and treat COVID-19. Authorised in eight countries, including US EUA. Retains neutralising activity against Omicron. US agreements for 1.2m doses.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5e97e5d-71d8-4780-a87f-b7fe484abdb9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Nature: doi.org/10.1038/s41586-021-04386-2 2. Includes doses shipped by sub-licensees. AstraZeneca invoiced supply is 963 million doses. 3. UK Health Security Agency: doi.org/10.1101/2021.12.14.21267615 4. The Lancet: doi.org/10.1016/S0140-6736(22)00094-0 5. Interim results from the D7220C00001 clinical trial. ATTR = transthyretin amyloidosis.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83aba8ff-ca1b-4119-8b90-5bcde14206cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Four NMEs approved in 2021: Saphnelo, Tezspire, Evusheld and Vaxzevria",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34d6dc44-9bc8-4f22-9dad-e1c410fbdadc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "BioPharmaceuticals: R&D pipeline highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8de976b-ddf2-4d88-9751-bb84c19121b6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 26,
      "from": 9,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "e1c98b8b-502c-44c3-8a4f-5b036b65dd56",
      "evidence": "The deck presents a golden circle narrative, highlighting why AstraZeneca is positioned for growth, how they will achieve it, and what the results are",
      "position": 0,
      "objective": "Why AstraZeneca is positioned for growth",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}